Study of Mometasone Furoate/Formoterol Fumarate Inhalation Combination in Healthy Volunteers
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00418509|
Recruitment Status : Completed
First Posted : January 5, 2007
Last Update Posted : June 22, 2007
|Condition or disease||Intervention/treatment||Phase|
|Healthy||Drug: Mometasone furoate Drug: Formoterol fumarate||Phase 1|
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||24 participants|
|Intervention Model:||Crossover Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Randomized, Single Dose, 3-Period Crossover Study to Evaluate the Dosage Form Proportionality, Dose Proportionality and Pharmacokinetics of Mometasone Furoate and Formoterol Fumarate From Three Combination MDI Formulations|
|Study Start Date :||November 2006|
- Dosage form and dose proportionality of mometasone and formoterol from combination metered dose inhalers (MDI).
- Extrapulmonary (systemic) effects and safety of mometasone and formoterol from combination MDI formulations.
- Plasma and urine concentrations mometasone and formoterol
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00418509
|Horsham, United Kingdom|
|Principal Investigator:||Novartis||Investigator site|